A Agilent Technologies Inc.

Agilent Announces Enhanced 8700 LDIR Chemical Imaging System for Microplastics Analysis

(NYSE: A) today announced the release of its enhanced , which has been further optimized for the analysis of microplastics in environmental samples. This newly improved package includes Clarity 1.5 software – a significant upgrade that advances the speed of analysis, enhances spectral acquisition, transformation, and library matching, and provides automated workflows for direct analysis of microplastics on a filter substrate. An innovative, redesigned sample holder allows the on-filter sample to be presented to the instrument more easily and consistently.

The prevalence of microplastics in the environment is a growing concern worldwide, prompting greater scrutiny from governments and increased monitoring of rivers and oceans by environmental agencies. Adequately assessing the prevalence of microplastics in the environment requires researchers to determine the size, shape, and chemical identity of plastic particles in a sample. As smaller particles are thought to be the most biologically relevant, this analysis must extend to particles on the micron scale.

Slow and complex analysis solutions are a major challenge to microplastics analysis and have hindered studies of real-world systems. Additionally, method variability limits the comparability of studies, making trends difficult to assess. Vibrational spectroscopy methods such as FTIR and Raman microscopy provide a useful alternative, but each faces limitations due to the excessive time of analysis and method complexity.

The Agilent 8700 LDIR brings high-speed analysis and ease of use to infrared spectroscopy and has rapidly emerged as the benchmark technique for the analysis of microplastics particles. The development of on-filter analysis for this platform marks another leap forward in speed and throughput. The ability to significantly increase testing volumes will allow a greater understanding of the extent of microplastics contamination in the environment and will help facilitate the development of appropriate standards and regulations.

Geoff Winkett, vice president and general manager for Agilent’s Molecular Spectroscopy Division, discussed the announcement’s impact. "When I speak with microplastics researchers, a recurring question is how to make testing faster and easier, as there is a real concern that the limited sample numbers that can be realistically processed may be masking the true nature of the issue," he said. "The fact is that other currently available techniques are too slow and cannot capture the extent of the microplastics load in drinking and environmental waters. Fast and easy-to-use analysis methods such as the 8700 LDIR provide an essential and much-needed alternative that enables researchers to increase sampling over area or time to address these limitations."

As a leading provider of analytical solutions for food and environmental analysis, Agilent is committed to delivering technology that improves user outcomes for academic research settings and commercial testing facilities. The release of the enhanced 8700 LDIR is expected to strengthen its leadership position in this growing market.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
03/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch